Pipobroman
| Pipobroman | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Overview[edit]
Pipobroman is a chemotherapy drug used primarily in the treatment of certain types of blood cancer, including polycythemia vera and chronic myelogenous leukemia. It is classified as an alkylating agent, which means it works by interfering with the DNA replication process in rapidly dividing cells, such as cancer cells.
Mechanism of Action[edit]
Pipobroman exerts its effects by forming covalent bonds with the DNA of cancer cells. This action leads to the cross-linking of DNA strands, ultimately inhibiting DNA synthesis and function. As a result, the proliferation of cancer cells is reduced, leading to cell death. This mechanism is similar to other alkylating agents used in chemotherapy.
Uses[edit]
Pipobroman is primarily indicated for the treatment of:
- Polycythemia vera: A condition characterized by the overproduction of red blood cells.
- Chronic myelogenous leukemia (CML): A type of cancer that affects the bone marrow and blood.
Side Effects[edit]
Like many chemotherapy drugs, pipobroman can cause a range of side effects. Common side effects include:
- Myelosuppression: A decrease in the production of blood cells, leading to conditions such as anemia, leukopenia, and thrombocytopenia.
- Gastrointestinal disturbances: Such as nausea, vomiting, and diarrhea.
- Alopecia: Hair loss.
Administration[edit]
Pipobroman is administered orally in the form of tablets. The dosage and treatment schedule depend on the specific condition being treated and the patient's response to the medication.
Precautions[edit]
Patients receiving pipobroman should be monitored regularly for blood counts and signs of toxicity. It is important to adjust the dosage based on the patient's hematological response to avoid severe myelosuppression.
History[edit]
Pipobroman was developed as part of efforts to find effective treatments for blood cancers. Its use has been somewhat limited due to the availability of newer agents with more favorable side effect profiles.
Related pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
